托西珠单抗与利妥昔单抗治疗中重度激素抵抗性格雷夫斯眼病的疗效比较
Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
机构信息
Centre Hospitalier National d'Ophtalmologie Des 15-20, Sorbonne Universités, Paris, France.
AP-HP, Hôpital Saint Antoine, Service De Médecine Interne Et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Universités, Paris, France.
出版信息
Ocul Immunol Inflamm. 2022 Feb 17;30(2):500-505. doi: 10.1080/09273948.2020.1808688. Epub 2020 Sep 23.
INTRODUCTION
To describe the efficacy of tocilizumab in patients with Graves' orbitopathy resistant or dependent to steroids and compare to rituximab treated patients.
PATIENTS AND METHODS
Graves's orbitopathy response was considered as decrease of at least 2 points of the CAS.
RESULTS
Twenty-one patients were included, 7 patients were treated with tocilizumab and 14 with rituximab. The primary was achieved in all 7 patients (100%) on tocilizumab and 9 out of 14 patients on (64%) rituximab ( = .17). Mean change in CAS was consistent with a decrease of 3.3 ± 0.5 points in patients on tocilizumab versus 2.5 ± 1.9 in patients on rituximab ( = .07). One patient on tocilizumab (14%) and 4 patients (29%) on rituximab experienced significant relapse during the follow-up. The difference in relapse-free survival was not significant in patients on tocilizumab (10.8 ± 4 months) compared with rituximab (17.88 ± 3.66).
CONCLUSION
We showed a significant improvement in the CAS, visual acuity, diplopia, and proptosis with both tocilizumab and rituximab.
简介
描述托珠单抗在对抗生素和免疫抑制剂治疗抵抗或依赖的格雷夫斯眼病患者中的疗效，并与利妥昔单抗治疗的患者进行比较。
患者和方法
格雷夫斯眼病反应被认为是 CAS 至少下降 2 分。
结果
共纳入 21 例患者，7 例患者接受托珠单抗治疗，14 例患者接受利妥昔单抗治疗。所有 7 例（100%）接受托珠单抗治疗的患者和 14 例（64%）接受利妥昔单抗治疗的患者均达到主要终点（ = 0.17）。接受托珠单抗治疗的患者的 CAS 平均变化一致，下降 3.3 ± 0.5 分，而接受利妥昔单抗治疗的患者下降 2.5 ± 1.9 分（ = 0.07）。1 例（14%）接受托珠单抗治疗的患者和 4 例（29%）接受利妥昔单抗治疗的患者在随访期间出现明显复发。接受托珠单抗治疗的患者无复发生存率（10.8 ± 4 个月）与接受利妥昔单抗治疗的患者（17.88 ± 3.66）无显著差异。
结论
我们发现托珠单抗和利妥昔单抗均能显著改善 CAS、视力、复视和眼球突出。
Zotero 插件